Kellie Young, Maria Aguilar, Robert Gish, Zobair Younossi, Sammy Saab, Taft Bhuket, Benny Liu, Aijaz Ahmed, Robert J. Wong – 27 June 2016 – Receiving Model for End‐Stage Liver Disease (MELD) exception status for hepatocellular carcinoma (HCC) improves wait‐list survival and probability of liver transplantation (LT). We aim to evaluate etiology‐specific disparities in MELD exception, LT wait‐list times, and post‐LT outcomes among patients with HCC listed for LT.

Jérôme Dumortier, Vincent Leroy, Christophe Duvoux, Victor de Ledinghen, Claire Francoz, Pauline Houssel‐Debry, Sylvie Radenne, Louis d'Alteroche, Claire Fougerou‐Leurent, Valérie Canva, Vincent di Martino, Filomena Conti, Nassim Kamar, Christophe Moreno, Pascal Lebray, Albert Tran, Camille Besch, Alpha Diallo, Alexandra Rohel, Emilie Rossignol, Armand Abergel, Danielle Botta‐Fridlund, Audrey Coilly, Didier Samuel, Jean‐Charles Duclos‐Vallée, Georges‐Philippe Pageaux – 27 June 2016 – Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrh

Takanobu Hara, Akihiko Soyama, Masaaki Hidaka, Amane Kitasato, Shinichiro Ono, Koji Natsuda, Tota Kugiyama, Hajime Imamura, Satomi Okada, Zhassulan Baimakhanov, Tamotsu Kuroki, Susumu Eguchi – 24 June 2016 – We retrospectively analyzed the causes, risk factors, and impact of early relaparotomy after adult‐to‐adult living donor liver transplantation (LDLT) on the posttransplant outcome. Adult recipients who underwent initial LDLT at our institution between August 1997 and August 2015 (n = 196) were included. Any patients who required early retransplantation were excluded.

24 June 2016

24 June 2016

24 June 2016

Markus Selzner, Nicolas Goldaracena, Juan Echeverri, Johan M. Kaths, Ivan Linares, Nazia Selzner, Cyril Serrick, Max Marquez, Gonzalo Sapisochin, Eberhard L. Renner, Mamatha Bhat, Ian D. McGilvray, Leslie Lilly, Paul D. Greig, Cynthia Tsien, Mark S. Cattral, Anand Ghanekar, David R. Grant – 24 June 2016 – The European trial investigating normothermic ex vivo liver perfusion (NEVLP) as a preservation technique for liver transplantation (LT) uses gelofusine, a non–US Food and Drug Administration–approved, bovine‐derived, gelatin‐based perfusion solution.

Vishwadeep Ahluwalia, James B. Wade, Melanie B. White, HoChong S. Gilles, Douglas M. Heuman, Michael Fuchs, Edith A. Gavis, Andrew Fagan, Felicia Tinsley, Dinesh Ganapathy, Leroy R. Thacker, Richard K. Sterling, R. Todd Stravitz, Puneet Puri, Arun J. Sanyal, Muhammad S. Siddiqui, Scott Matherly, Velimir Luketic, Joel Steinberg, F. Gerard Moeller, Jasmohan S. Bajaj – 24 June 2016 – The functional basis of cognitive and quality of life changes after liver transplant is unclear.

Akihiko Soyama, Susumu Eguchi, Hiroto Egawa – 24 June 2016 – As of December 31, 2014, 7937 liver transplants (7673 living donor transplants and 264 deceased donor liver transplantations [DDLTs; 261 from heart‐beating donors and 3 from non–heart‐beating donors]) have been performed in 67 institutions in Japan. The revised Organ Transplant Law in Japan came into effect in July 2010, which allows organ procurement from brain‐dead individuals, including children, with family consent if the patient had not previously refused organ donation.

Sarah K. Alver, Douglas J. Lorenz, Michael R. Marvin, Guy N. Brock – 24 June 2016 – The United Network for Organ Sharing (UNOS) recently implemented a 6‐month delay before granting exception points to liver transplantation candidates with hepatocellular carcinoma (HCC) to address disparity in transplantation access between HCC and non‐HCC patients. An HCC‐specific scoring scheme, the Model for End‐Stage Liver Disease equivalent (MELDEQ), has also been developed.